12,372 trials
Pediculosis
Primary: Proportion of Index Subjects Free of Any Lice 14 Days After Their Last Treatment in the Modified ITT (LOCF) — 86.67; 45.33 percentage of subjects — p=<0.0001
Hepatitis C
Primary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 81.3; 50.0 Percentage of participants…
Congenital Bleeding Disorder · Congenital FXIII Deficiency
Primary: Area Under the Concentration vs. Time Curve (AUC) — 250.25 IU*h/mL
Influenza
Primary: Geometric Mean Titers in Subjects After Receiving One Dose of Lot 1 or Lot 2 or Lot 3 of aTIV — 209; 187; 199; 548 Titers
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Number of Satisfying Sexual Events — 1.0; 0.6 sexual events
Post-operative Pain
Primary: The Postoperative Opioid Requirement After Mastectomy — 9; 7.5 milligram (mg)
Congenital Bleeding Disorder · Haemophilia A
Primary: The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)) — 0 N with Inhibitors / N with ≥50 EDs
Healthy
Primary: Serum Estradiol Levels by Cycle Day — 47.00; 51.50; 62.50; 34.50 pg/mL — p=0.6346
Rheumatoid Arthritis
Primary: Percentage of Participants With Low Disease Activity Score at Week 24 — 57 Percentage of Participants — p=<0.001
Colorectal Cancer
Primary: Progression-free Survival — 9.1; 5.1 Months — p=<0.001
Pregnancy · Polycystic Ovary Syndrome
Primary: Live Birth — 72; 103 Participants — p=0.007
Hereditary Angioedema
Primary: Time to Onset of Symptom Relief. — 2.0; 12.0 Hours — p=< 0.001
Transtibial Amputation
Primary: Metabolic Oxygen Consumption During Ambulation — 3.45; 3.13; 2.97 Watts per kilogram
Attention-deficit/Hyperactivity Disorder
Primary: Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal Phase — 64.9; 49.3 percentage of treatment failures — p=0.006
Asthma
Primary: Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period — 0.366…